Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector

[1]  B. Sorrentino.  Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs , 2002, Nature Reviews Cancer.

[2]  T. Schumacher,et al.  Immunotherapy through TCR gene transfer , 2001, Nature Immunology.

[3]  R. Tsien,et al.  Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signaling using spectral variants of the green fluorescent protein. , 2001, Cytometry.

[4]  W. Ostertag,et al.  Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy , 2001, Gene Therapy.

[5]  E. ten Dam,et al.  The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. , 2001, The Journal of general virology.

[6]  D Gani,et al.  Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. , 2001, The Journal of general virology.

[7]  D. Wiest,et al.  On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. , 2000, Immunity.

[8]  H. Mizuguchi,et al.  IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  D. Vignali,et al.  Profound enhancement of T cell activation mediated by the interaction between the TCR and the D3 domain of CD4. , 1999, Journal of immunology.

[10]  M. Izquierdo,et al.  Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy , 1999, Gene Therapy.

[11]  Jianzhu Chen,et al.  T Lymphocyte Development in the Absence of CD3ε or CD3γδεζ , 1999, The Journal of Immunology.

[12]  S. Moriuchi,et al.  Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. , 1998, Cancer research.

[13]  A. Nienhuis,et al.  Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells , 1998, Nature Medicine.

[14]  G. Palù,et al.  Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer , 1998, Gene Therapy.

[15]  A. Nienhuis,et al.  An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. , 1998, Blood cells, molecules & diseases.

[16]  S. Jane,et al.  Development of high-titer retroviral producer cell lines by using Cre-mediated recombination , 1997, Journal of virology.

[17]  D. Vignali,et al.  T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. , 1997, Immunity.

[18]  Richard J Smeyne,et al.  Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. , 1997, Blood.

[19]  M. Ryan,et al.  Virus-encoded proteinases of the picornavirus super-group. , 1997, The Journal of general virology.

[20]  Philippe Le Mercier,et al.  Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. , 1997, Nucleic acids research.

[21]  F. Levine,et al.  Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter. , 1996, Gene.

[22]  V. Pathak,et al.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy , 1995, Journal of virology.

[23]  L. Zitvogel,et al.  Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. , 1994, Human gene therapy.

[24]  A. Singer,et al.  T cell development in mice that lack the zeta chain of the T cell antigen receptor complex. , 1993, Science.

[25]  G. Parks,et al.  Proteolytic processing of the cardioviral P2 region: primary 2A/2B cleavage in clone-derived precursors. , 1992, Virology.

[26]  M. Ryan,et al.  Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. , 1991, The Journal of general virology.

[27]  J. Lippincott-Schwartz,et al.  The T cell antigen receptor: insights into organelle biology. , 1990, Annual review of cell biology.

[28]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[29]  M. Emerman,et al.  Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism , 1984, Cell.